Anthraquinone anticancer drugs
US6465522B1 · kind B1 · utility
6Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 7, 2001 |
| Grant date | Oct 15, 2002 |
| Priority date | — |
| Expiry date | Nov 7, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A molecule of formula (I); wherein:X is a halogen, or a substituted sulfonate group;m=1-5;n=1-5;R1, R2=H, C1-4 lower alkyl or C1-4 lower alkyl chain having additional functionality; andthe amino group −NR1R2 linked to the anthraquinone is primary, secondary or tertiary or is a tertiary group in the N-oxide form having the formula —N(O)R1R2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.